Physician profile
Kathlene J Ayala
NPI 1831695519
$4,468.86
in general payments reported to CMS, 2019-2025
13 companies · $523 in 2025
The $523 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $276 · 2022: $700 · 2023: $1,902 · 2024: $1,068 · 2025: $523.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,011 · Travel and Lodging: $481.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,011.45 |
| Travel and Lodging | $481.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,079.47 | 2021-2025 | Cobalt Dr Mri Surescan, Azure Xt Dr Mri Surescan, Linq II |
| Abbott Laboratories | $610.47 | 2021-2025 | Gallant, Assurity, Aveir |
| E.R. Squibb & Sons, L.L.C. | $376.65 | 2023-2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $263.31 | 2021-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $262.53 | 2021-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $257.27 | 2022-2025 | |
| Boston Scientific Corporation | $185.13 | 2022 | |
| Cvrx, INC. | $158.75 | 2023 | Barostim Neo System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $79.57 | 2022 | |
| Amgen INC. | $72.86 | 2023-2024 | Repatha |
| Pfizer INC. | $65.73 | 2023-2024 | |
| Organogenesis INC. | $32.34 | 2024 | |
| Agepha Pharma Fz LLC | $24.78 | 2024 | Lodoco |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathlene Ayala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.